LY9

Summary

LY9 (lymphocyte antigen 9, HGNC:6730) is a protein-coding gene on chromosome 1q23.3, encoding T-lymphocyte surface antigen Ly-9 (Q9HBG7). Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family.

LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).

Source: NCBI Gene 4063 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 115 total
• MANE Select transcript: NM_002348

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6730
Approved symbol	LY9
Name	lymphocyte antigen 9
Location	1q23.3
Locus type	gene with protein product
Status	Approved
Aliases	CD229, mLY9, SLAMF3, hly9
Ensembl gene	ENSG00000122224
Ensembl biotype	protein_coding
OMIM	600684
Entrez	4063

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 11 protein_coding, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000263285, ENST00000368035, ENST00000368037, ENST00000368039, ENST00000392203, ENST00000471816, ENST00000474998, ENST00000479663, ENST00000480837, ENST00000485624, ENST00000490902, ENST00000873847, ENST00000873848, ENST00000873849, ENST00000873850, ENST00000873851, ENST00000873852

RefSeq mRNA: 4 — MANE Select: NM_002348 NM_001033667, NM_001261456, NM_001261457, NM_002348

CCDS: CCDS30916, CCDS30917, CCDS65695, CCDS65696

Canonical transcript exons

ENST00000263285 — 10 exons

Exon	Start	End
ENSE00000789190	160819321	160819374
ENSE00000789192	160824181	160824249
ENSE00000958829	160796174	160796311
ENSE00000958831	160823465	160823796
ENSE00001166088	160816594	160816863
ENSE00001228897	160818218	160818319
ENSE00001228917	160827748	160828255
ENSE00003500890	160799753	160800082
ENSE00003540463	160813636	160813911
ENSE00003634771	160814420	160814761

Expression profiles

Bgee: expression breadth ubiquitous, 181 present calls, max score 92.00.

FANTOM5 (CAGE): breadth broad, TPM avg 7.7981 / max 648.1966, expressed in 347 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6182	6.1085	326
6183	1.0305	181
6180	0.4329	121
6181	0.1295	68
6179	0.0966	59

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	92.00	gold quality
lymph node	UBERON:0000029	91.21	gold quality
buccal mucosa cell	CL:0002336	90.86	gold quality
blood	UBERON:0000178	89.44	gold quality
spleen	UBERON:0002106	88.10	gold quality
bone marrow cell	CL:0002092	87.05	gold quality
colonic epithelium	UBERON:0000397	85.61	gold quality
bone marrow	UBERON:0002371	84.74	gold quality
superficial temporal artery	UBERON:0001614	83.42	gold quality
vermiform appendix	UBERON:0001154	82.99	gold quality
trabecular bone tissue	UBERON:0002483	82.29	gold quality
tonsil	UBERON:0002372	82.26	gold quality
epithelium of nasopharynx	UBERON:0001951	82.08	gold quality
nasopharynx	UBERON:0001728	82.07	gold quality
amniotic fluid	UBERON:0000173	80.25	gold quality
caecum	UBERON:0001153	79.99	gold quality
thymus	UBERON:0002370	79.08	gold quality
olfactory bulb	UBERON:0002264	77.77	gold quality
type B pancreatic cell	CL:0000169	77.71	gold quality
parotid gland	UBERON:0001831	76.34	gold quality
rectum	UBERON:0001052	76.10	gold quality
small intestine Peyer’s patch	UBERON:0003454	75.14	gold quality
leukocyte	CL:0000738	74.73	gold quality
mucosa of transverse colon	UBERON:0004991	74.35	gold quality
small intestine	UBERON:0002108	73.53	gold quality
gall bladder	UBERON:0002110	73.38	gold quality
mononuclear cell	CL:0000842	73.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	72.97	gold quality
monocyte	CL:0000576	72.93	gold quality
jejunal mucosa	UBERON:0000399	72.06	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	878.75
E-CURD-122	yes	93.67
E-CURD-88	yes	51.49
E-ANND-3	yes	36.43
E-MTAB-8142	yes	14.73
E-MTAB-6678	yes	4.60
E-MTAB-9067	yes	4.53
E-ENAD-27	no	3.93

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting LY9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-4506	99.34	67.47	526
HSA-MIR-12113	99.32	67.54	1072
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-4504	99.10	69.14	1328
HSA-MIR-4650-3P	99.01	68.39	1062
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-3074-5P	98.82	66.56	1414
HSA-MIR-4539	98.78	67.18	888
HSA-MIR-581	98.39	67.42	835
HSA-MIR-599	98.32	66.99	1037
HSA-MIR-595	98.25	67.44	699
HSA-MIR-3921	97.81	67.45	1431
HSA-MIR-6747-3P	97.73	64.84	1596
HSA-MIR-4653-5P	97.22	67.72	1429
HSA-MIR-592	96.59	67.59	817
HSA-MIR-3675-5P	95.90	65.80	474

Literature-anchored findings (GeneRIF, showing 22)

• Both mouse and human novel Ly9 genes mapped close to the CD229 gene in a region where other members of the CD150 family have also been mapped. (PMID:12242590)
• CD229, but not other members of the CD150 family, directly bind Grb2. (PMID:15879090)
• CD229 is a self-ligand, interacting through its N-terminal V-like domain which contains three amino acid residues critical for the homophilic binding interaction. (PMID:15905546)
• A family-based association study in the United Kingdom and Canada identifies genetic variants in the LY9 promoter and coding region contributing to systemic lupus erythematosus susceptibility. (PMID:18216865)
• CD229 is specifically over-expressed on myeloma cells including their clonogenic precursors and contributes to their malignant phenotype. (PMID:21606160)
• SLAMF3 and SLAMF6 T cell surface expression and IL-17 levels significantly correlate with disease activity in systemic lupus erythematosus patients (PMID:22184727)
• Data indicate that the dominance of the SLAMF3/SLAMF6 pathway in inducing IL-17A production can be attributed to an increased nuclear abundance and recruitment of RORgammat to the IL17A promoter. (PMID:22989874)
• These results suggest a role for CD319 and CD229 in the systemic lupus erythematosus disease process. (PMID:23956418)
• SLAMF3 is an inhibitor of hepatocellular carcinoma cell proliferation and tumor progression. (PMID:24376606)
• Results revealed that SLAMF3 plays a role during hepatitis C virus entry, likely by enhancing entry of viral particle within hepatocytes. (PMID:24927415)
• study showed CD229 is overexpressed on the malignant plasma cells of patients across all types of plasma cell dyscrasias including multiple myeloma; CD229 is also expressed on the surface of a fraction of cells carrying the phenotype of chemotherapy-resistant and myeloma-propagating cells within the patients’ bone marrow (PMID:26001047)
• the Val602 variant of the non-synonymous single nucleotide polymorphism (SNP) rs509749 in the SLAM family member CD229 (Ly9, SLAMF3) has a two-fold lower affinity compared with the SLE-associated Met602 variant for the small adaptor protein SAP (PMID:26221972)
• CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance. (PMID:26303094)
• the results presented here suggest that the tumor suppressor potential of SLAMF3 occurs through activation of Retinoblastoma protein that represses PLK1. (PMID:26799423)
• Authors make a strong correlation between induced SLAMF3 overexpression and the specific loss of MRP-1 expression and its functionalities as a drugs resistance transporter. (PMID:27081035)
• CD229 is a reliable new alternative PC-gating marker in routine laboratory practice. (PMID:29316178)
• Viral Ly9 homologs are new manipulators of host immunity. (Review) (PMID:30791129)
• SLAMF3 expression is upregulated on T cells from type 2 diabetes patients and associated with T-cell activation and cytokine production. (PMID:31332162)
• SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. (PMID:31974290)
• The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma. (PMID:32818503)
• CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation. (PMID:36445333)
• SLAMF3 promotes Th17 differentiation and is reversed by iguratimod through JAK1/STAT3 pathway in primary Sjogren’s syndrome. (PMID:38061117)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:cabz01074946.1	ENSDARG00000090396
mus_musculus	Ly9	ENSMUSG00000004707
rattus_norvegicus	Ly9	ENSRNOG00000025069

Paralogs (9): SLAMF7 (ENSG00000026751), CD84 (ENSG00000066294), CD2 (ENSG00000116824), SLAMF1 (ENSG00000117090), CD48 (ENSG00000117091), CD244 (ENSG00000122223), SLAMF8 (ENSG00000158714), SLAMF9 (ENSG00000162723), SLAMF6 (ENSG00000162739)

Protein

Protein identifiers

T-lymphocyte surface antigen Ly-9 — Q9HBG7 (reviewed: Q9HBG7)

Alternative names: Cell surface molecule Ly-9, Lymphocyte antigen 9, SLAM family member 3, Signaling lymphocytic activation molecule 3

All UniProt accessions (6): A0A0C4DFU4, Q5VYH9, Q5VYI1, Q9HBG7, R4GNG7, V9GY30

UniProt curated annotations — full annotation on UniProt →

Function. Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A. Promotes recruitment of RORC to the IL-17 promoter. May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4(+) T-cells. May negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells.

Subunit / interactions. Interacts with SH2D1A, SH2D1B and INPP5D. Interacts (via phosphorylated cytoplasmic domain) with PTPN11; the interaction is blocked by SH2D1A.

Subcellular location. Membrane. Cell membrane.

Tissue specificity. Increased surface expression on T-cells of systemic lupus erythematosus (SLE) patients.

Domain organisation. The ITSMs (immunoreceptor tyrosine-based switch motifs) with the consensus sequence T-X-Y-X-X-[VI] present in SLAM family receptors have overlapping specificity for activating and inhibitory SH2 domain-containing binding partners. Especially they mediate the interaction with the SH2 domain of SH2D1A and SH2D1B. A ’three-pronged’ mechanism is proposed involving threonine (position -2), phosphorylated tyrosine (position 0) and valine/isoleucine (position +3).

Isoforms (4)

UniProt ID	Names	Canonical?
Q9HBG7-1	1	yes
Q9HBG7-2	2
Q9HBG7-3	3
Q9HBG7-4	4

RefSeq proteins (4): NP_001028839, NP_001248385, NP_001248386, NP_002339* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR015631	CD2/SLAM_rcpt	Family
IPR036179	Ig-like_dom_sf	Homologous_superfamily

UniProt features (33 total): glycosylation site 8, disulfide bond 4, splice variant 4, domain 4, region of interest 2, short sequence motif 2, topological domain 2, signal peptide 1, chain 1, compositionally biased region 1, modified residue 1, transmembrane region 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HBG7-F1	66.27	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 603

Disulfide bonds (4): 172–242, 178–222, 377–446, 383–427

Glycosylation sites (8): 68, 95, 120, 169, 173, 285, 413, 424

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 253 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, MORF_MSH3, MODULE_255, GOBP_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, MORF_BRCA1, GOBP_ALPHA_BETA_T_CELL_DIFFERENTIATION, MODULE_317, GOCC_CELL_SURFACE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_CD4_POSITIVE_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_T_CELL_DIFFERENTIATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_CYTOKINE_PRODUCTION, GOBP_POSITIVE_T_CELL_SELECTION

GO Biological Process (8): immune response (GO:0006955), cell adhesion (GO:0007155), positive regulation of interleukin-17 production (GO:0032740), T cell activation (GO:0042110), innate immune response (GO:0045087), T-helper 17 cell lineage commitment (GO:0072540), adaptive immune response (GO:0002250), immune system process (GO:0002376)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune response	2
cellular anatomical structure	2
immune system process	1
response to stimulus	1
cellular process	1
positive regulation of cytokine production	1
interleukin-17 production	1
regulation of interleukin-17 production	1
lymphocyte activation	1
defense response to symbiont	1
T-helper cell lineage commitment	1
T-helper 17 cell differentiation	1
biological_process	1
binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1

Protein interactions and networks

STRING

1324 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LY9	SH2D1B	O14796	937
LY9	SH2D1A	O60880	932
LY9	CD48	P09326	925
LY9	CD2	P06729	750
LY9	SLAMF1	Q13291	637
LY9	SLAMF8	Q9P0V8	627
LY9	CD58	P19256	589
LY9	PTPN11	Q06124	575
LY9	NCR1	O76036	511
LY9	SRC	P12931	495
LY9	DOK2	O60496	479
LY9	GRB2	P29354	464
LY9	CD244	Q9BZW8	461
LY9	VAV1	P15498	459
LY9	ATP1A2	P50993	458

IntAct

6 interactions, top by confidence:

A	B	Type	Score
SH2D1A	LY9	psi-mi:“MI:0407”(direct interaction)	0.440
INPP5D	LY9	psi-mi:“MI:0407”(direct interaction)	0.440
LY9	LY9	psi-mi:“MI:0407”(direct interaction)	0.440
LY9	GUSB	psi-mi:“MI:0914”(association)	0.350
LY9	purL	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (12): AP2M1 (Two-hybrid), LY9 (Affinity Capture-Western), LY9 (Two-hybrid), LY9 (Affinity Capture-Western), LY9 (Two-hybrid), PTPN11 (Affinity Capture-Western), Sh2d1b1 (Affinity Capture-Western), EDEM3 (Affinity Capture-MS), GUSB (Affinity Capture-MS), HLA-F (Affinity Capture-MS), DDX19B (Affinity Capture-MS), IDUA (Affinity Capture-MS)

ESM2 similar proteins: A0A0B4J1G0, A0A0B4J1L0, A0A0G2KBC9, A1YIY0, A8MTB9, B6A8R8, C0HJX2, C0HJX3, E2RP87, H0VDZ8, P08637, P09326, P12314, P23505, P26151, P43626, P43627, P43628, P43631, P43632, P83555, P83556, Q01965, Q13291, Q14952, Q14953, Q14954, Q28942, Q2YHT5, Q61400, Q61450, Q640U3, Q68EV1, Q68SN8, Q6UX41, Q6UXE8, Q6UY09, Q6XJV4, Q6XPU4, Q7TST0

Diamond homologs: A4FUY1, A6QQC6, A8MVW5, D3YXG0, D3ZB51, D3ZQE1, E9PZ19, O08775, P13595, P13596, P16573, P31809, P35968, P52583, Q00889, Q14CZ8, Q3KPI0, Q4VAH7, Q52KR2, Q62845, Q640R3, Q69Z26, Q9D2Z1, Q9HBG7, Q9UPX0, Q01965, Q18PI6, Q8BHK6, Q96A28, Q96DU3, Q9D780, Q9NQ25, Q9UIB8, O94898, P35918, Q5GIT4, Q810J1, Q9ET39, P11464, Q00887

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

115 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	92
Likely benign	11
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1760 predictions. Top by Δscore:

Variant	Effect	Δscore
1:160796310:GG:G	donor_gain	1.0000
1:160796311:GG:G	donor_gain	1.0000
1:160816725:G:GT	donor_gain	1.0000
1:160796307:CATGG:C	donor_gain	0.9900
1:160796309:TGG:T	donor_gain	0.9900
1:160796309:TGGG:T	donor_loss	0.9900
1:160796310:GGG:G	donor_gain	0.9900
1:160796310:GGGTA:G	donor_loss	0.9900
1:160796311:GGTAA:G	donor_loss	0.9900
1:160796312:G:GG	donor_gain	0.9900
1:160796312:GT:G	donor_loss	0.9900
1:160796313:TAAG:T	donor_loss	0.9900
1:160799899:C:G	acceptor_gain	0.9900
1:160814762:G:GG	donor_gain	0.9900
1:160818318:GT:G	donor_gain	0.9900
1:160818320:G:GG	donor_gain	0.9900
1:160796308:ATGG:A	donor_gain	0.9800
1:160800079:TATGG:T	donor_loss	0.9800
1:160800080:ATGG:A	donor_loss	0.9800
1:160800081:TGG:T	donor_loss	0.9800
1:160800082:GGTGA:G	donor_loss	0.9800
1:160800083:GTG:G	donor_loss	0.9800
1:160800084:T:A	donor_loss	0.9800
1:160800085:G:GT	donor_loss	0.9800
1:160818314:G:GT	donor_gain	0.9800
1:160827746:AGGT:A	acceptor_gain	0.9800
1:160827747:GGTG:G	acceptor_gain	0.9800
1:160800086:AGT:A	donor_loss	0.9700
1:160800087:G:C	donor_loss	0.9700
1:160816826:G:GT	donor_gain	0.9700

AlphaMissense

4280 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:160813754:G:C	W191C	0.989
1:160813754:G:T	W191C	0.989
1:160799868:G:C	W80C	0.987
1:160799868:G:T	W80C	0.987
1:160799866:T:A	W80R	0.986
1:160799866:T:C	W80R	0.986
1:160813845:T:A	C222S	0.986
1:160813846:G:C	C222S	0.986
1:160800064:T:C	F146L	0.985
1:160800066:C:A	F146L	0.985
1:160800066:C:G	F146L	0.985
1:160813752:T:A	W191R	0.985
1:160813752:T:C	W191R	0.985
1:160813845:T:C	C222R	0.984
1:160813847:C:G	C222W	0.984
1:160800013:T:G	Y129D	0.982
1:160813713:T:C	C178R	0.981
1:160813846:G:A	C222Y	0.981
1:160813713:T:A	C178S	0.979
1:160813714:G:C	C178S	0.979
1:160814535:G:C	W282C	0.978
1:160814535:G:T	W282C	0.978
1:160814692:T:G	Y335D	0.977
1:160813708:T:C	L176P	0.974
1:160814533:T:A	W282R	0.974
1:160814533:T:C	W282R	0.974
1:160816800:T:A	C427S	0.974
1:160816801:G:C	C427S	0.974
1:160800020:C:A	A131D	0.973
1:160816709:G:C	W396C	0.972

dbSNP variants (sampled 300 via entrez): RS1000015217 (1:160828446 T>A), RS1000058821 (1:160801974 G>A,T), RS1000111302 (1:160804457 T>G), RS1000162886 (1:160808757 T>C,G), RS1000258158 (1:160822485 C>T), RS1000376027 (1:160797156 A>G), RS1000462995 (1:160810668 C>T), RS1000505412 (1:160806254 C>T), RS1000569578 (1:160807663 G>A), RS1000754138 (1:160794729 A>G), RS1001134693 (1:160819110 C>CAG), RS1001289060 (1:160816184 C>A,T), RS1001327563 (1:160797798 T>C), RS1001362819 (1:160804189 C>T), RS1001532608 (1:160821159 A>C)

Disease associations

OMIM: gene MIM:600684 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004627_130	Lymphocyte count	3.000000e-11
GCST004632_97	Lymphocyte percentage of white cells	2.000000e-11
GCST90002388_629	Lymphocyte count	5.000000e-39
GCST90002389_75	Lymphocyte percentage of white cells	4.000000e-18
GCST90002407_8	White blood cell count	6.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	2
Nickel	increases expression	2
triphenyl phosphate	affects expression	1
perfluorooctanoic acid	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
avobenzone	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	decreases expression	1
(+)-JQ1 compound	decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Arsenic	affects methylation	1
Aspirin	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases expression	1
Hydrogen Peroxide	decreases expression	1
Ibuprofen	decreases expression	1
Lipopolysaccharides	increases expression, affects cotreatment, decreases expression, affects response to substance	1
Testosterone	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	decreases expression	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.